Market Trends of Cancer Cachexia Industry
Appetite Stimulators is Expected to Grow Significantly in the Cancer Cachexia Market
Cancer patients frequently develop loss of appetite and weight loss. Unintended weight loss and anorexia (the loss of appetite or desire to eat) in patients with cancer is associated with decreased performance status, reduced response and tolerance to treatment, decreased survival, and reduced quality of life, highlighting the need for effective Cancer Anorexia Treatment options. Therefore, the increasing use of an Cancer Appetite Stimulant could be considered for patients who exhibit decreased appetite. The increasing prevalence of Cancer Cachexia cases is one of the major factors propelling the overall market's growth.
According to an article published by PubMed in March 2022, pharmacologic interventions for cancer-related anorexia are very limited. International guidelines recommend promoting anabolism through appetite stimulants which help in nutritional, physical, and pharmacologic therapies, forming an integral part of Cancer Nutrition Therapy. According to an article published by PubMed Central in August 2021, cachexia is a syndrome of metabolic disturbance characterised by inflammation and loss of muscle with or without loss of adipose tissue. In Cancer Cachexia, a multifaceted condition, patients suffer from loss of body weight and muscle, necessitating effective Muscle Wasting Treatment that can improve quality of life and survival. Thus, the high burden of Cancer Cachexia in quality of life of the patients is expected to increase the research and development activities regarding appetite stimulators for Cancer Cachexia, thus enhancing the segment growth.
With the growing burden of cancer worldwide, market players are investing steadily in innovative products and their R&D, thus boosting the market's growth. For instance, in March 2020, Pfizer Inc., a global pharmaceutical major, launched a global 12-week open-label study that will explore how its drug, PF-06946860, is tolerated in patients with Cancer Cachexia. Hence, such factors may help the appetite stimulators segment achieve a high growth rate in the future, further driving the growth of the Cachexia Treatment Market.
North America is Expected to Dominate the Cancer Cachexia Market
North America is expected to dominate the Cancer Cachexia Market due to the high burden of cancer and Cancer Cachexia, the presence of many drug manufacturers, and the advancing paradigm of care for cancer patients. According to the estimates of GLOBOCAN 2020, there are around 195,499 new cases of cancer in Mexico. Furthermore, according to the American Cancer Society 2022, there will be an estimated 1.9 million new cancer cases diagnosed in the United States in 2022.
Advancements in novel technology for the treatment of Cancer Cachexia and a strong product pipeline for Wasting Syndrome have also helped in the growth of the Wasting Syndrome Market in the region. For instance, according to the data from clinicaltrials.gov in October 2022, a phase 1 clinical trial was started by the United States-based AVEO Pharmaceuticals, Inc. in February 2022, the study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia. Hence, due to such factors, the Cachexia Treatment Market is expected to grow in the region.
